

Figure S3

Sample	Sex	Age	Type	ELN	FAB	CG	Somatic Mutation	WBC	HGB	PLT
SU209	F	66	de novo	INT	M2	46XY	NPM1, FLT3, NOTCH2	166	8.8	133
SU266	M	65	de novo	Adverse	-	Inv(3)	SETD2, TET2, AK2, ASXL1, FLT3-ITD	374	9.9	36
SU351	M	75	secondary MDS-AML	Adverse	M5	Complex	IDH2, NRAS, BCORL1, SETD	3.2	9.7	26
SU353	M	66	de novo	INT	M4	46XY	NPM1, FLT3-ITD, DNMT3A,	111	9.6	73
SU456	M	55	secondary MDS-AML	Adverse	-	Complex	NRAS, TP53	1.8	7.6	146
SU480	F	64	de novo	INT	M1	46XX	CEPBA, FLT3-ITD, DNMT3A, TET2, BCOR, ZRSR2, TET2	16.9	7.4	112
SU496	M	24	de novo	INT	-	(+) ⁸	TP53, IDH2, DNMT3A, STAG2, BCOR, ZRSR2, TET2	35.4	10.3	44
SU540	F	68	de novo	INT	-	46XX	DNMT3A, MYC, CEPBA, NPM1, FLT3-ITD, TET2	94.4	5.6	189
SU555	F	27	de novo	INT	-	-	PTPN11, SETD2, MTND5	103.2	7.5	28
SU575	M	72	secondary MDS-AML	INT	-	46XY	NPM1, FLT3-ITD, DNMT2, ZRSR2, JAK3	28.4	8.3	23

Patient and disease-specific characteristics of human AML samples investigated here.

ELN: European Leukemia Net risk category; FAB: French-American-British AML classification; CG: cytogenetics; WBC: white blood cell ($10^3/\mu\text{l}$); HGB: hemoglobin (g/dL); PLT: platelet ($10^3/\mu\text{L}$).